Cetuximab biosimilar - Shanghai Zhangjiang Biotechnology

Drug Profile

Cetuximab biosimilar - Shanghai Zhangjiang Biotechnology

Alternative Names: CMAB-009

Latest Information Update: 08 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shanghai Zhangjiang Biotechnology
  • Developer Shanghai Biomabs Pharmaceuticals; Shanghai Zhangjiang Biotechnology
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Colorectal cancer

Most Recent Events

  • 17 May 2017 Efficacy and adverse event data from a phase II/III trial in Colorectal cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Dec 2015 Shanghai Zhangjiang Biotechnology completes a phase II/III trial in Colorectal cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in China (NCT01550055)
  • 30 May 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top